Renaming Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) aims to improve understanding and treatment of the hormonal disorder affecting over 170 million women globally, including symptoms like irregular periods, excess hair growth, and infertility risks.
Polycystic Ovary Syndrome (PCOS), affecting over 3 million UK women, is renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) to reflect its complex hormonal nature, aiming to improve diagnoses and treatment.
Polycystic ovary syndrome (PCOS) has been renamed to polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its systemic impact beyond ovarian cysts, affecting nearly one in eight women globally
Polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS), a move which health experts say will lead to faster diagnosis and better treatment for women of all ages.
Despite what the name suggests, women with polycystic ovary syndrome (PCOS) do not have a higher rate of abnormal ovarian cysts than the general population, a large study shows.
